Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
AD HOC NEWS Earnings
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is …
Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a "Moderate Buy" consensus and an average price target of $275.50, …
Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a "Moderate Buy" consensus with an average price target of $158.04. …
Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …
Confluence Wealth Services Inc. significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 251.4% during the second quarter, acquiring an additional 7,986 shares, bringing its total holdings to 11,162 shares valued at $1.41 million. Gilead reported strong Q2 revenue of $7.80 billion, exceeding …
5 Revealing Analyst Questions From Eli Lilly's Q2 Earnings Call Eli Lilly's second quarter was marked by a positive market reaction, despite the company missing Wall Street's revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. …
Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the …
Gilead Sciences (GILD) shares have dropped 11.3% in the last six months, significantly underperforming the S&P 500. The article expresses low confidence in GILD due to disappointing long-term revenue growth (2.7% CAGR over five years), a shrinking adjusted operating margin (down 34.2 percentage points …
Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …
Sharemaestro market context Price below Trend Line 52 weeks +4.1%On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …
Merck & Co., Inc. EVP Chirfi Guindo recently sold 10,000 shares of the company's stock for $1.35 million, reducing his direct ownership by over 21%. This sale occurred as MRK shares traded near a 52-week high and the company reported strong quarterly revenues that …
The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from …
On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached £8.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed …
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this …
Sharemaestro market context Trend signal active 52 weeks +57.8%Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval for ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy. This approval, based on …
AbbVie Inc. reported strong first-quarter 2026 financial results with significant revenue growth driven by Skyrizi and Rinvoq, and raised its full-year EPS guidance. The company also secured European approval for Boey, expanding its aesthetic portfolio. Analysts remain largely positive, though concerns about elevated debt …
Chirfi Guindo, EVP, Access, Policy & Comms at Merck & Co., Inc. (MRK), sold 10,000 shares of common stock on August 13, 2026, at a price of $135.00 per share. This open market transaction reduced his direct holdings to 36,613.127 shares. The sale, valued …
Merck & Co., Inc. (MRK) stock reached a new 52-week high after Daiwa Securities upgraded it to "outperform" with a $143 price target. The company reported strong Q2 revenue of $16.61 billion, exceeding analyst estimates, driven by Keytruda and other oncology products. Despite recent …
The U.S. FDA has approved Bristol Myers Squibb's combination treatment, iberdomide, for patients with a rare form of blood cancer called multiple myeloma. This treatment is intended for patients whose illness has relapsed or not responded to other therapies. Iberdomide works by targeting the …
Merck's EVP and General Counsel, Jennifer Zachary, exercised stock options for a total of 54,927 shares and subsequently sold 80,315 common shares on August 12, 2026. The shares were sold at a weighted average price of $133.4557, totaling approximately $10.72 million in gross proceeds. …
Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …
Search by ticker symbol or company name and select a result to open its chart.